DE4238159A1 - Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon - Google Patents

Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon

Info

Publication number
DE4238159A1
DE4238159A1 DE19924238159 DE4238159A DE4238159A1 DE 4238159 A1 DE4238159 A1 DE 4238159A1 DE 19924238159 DE19924238159 DE 19924238159 DE 4238159 A DE4238159 A DE 4238159A DE 4238159 A1 DE4238159 A1 DE 4238159A1
Authority
DE
Germany
Prior art keywords
diabetes
interferon
treatment
gamma
prim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19924238159
Other languages
German (de)
Inventor
Josef Dr Med Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19924238159 priority Critical patent/DE4238159A1/en
Publication of DE4238159A1 publication Critical patent/DE4238159A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Treatment of prim. chronic polyarthritis and diabetes is effected by admin. of gamma-interferon (I). Studies have shown that treatment of rheumatic patients also afflicted with type II diabetes with (I) cures both the rheumatism and the diabetes. Patients with type I diabetes have been treated with partial success (when the beta-islet cells are still functional). It has been found that diabetics have higher antigen levels in their beta-islet cell walls than healthy subjects, stimulating prodn. of autoimmune antibodies, and that (I) blocks this immume reaction and thus inhibits degeneration of the islet cells. (I) has no side effects that might weaken the immune system.

Description

Während der Teilnahme an einer Therapiestudie fur die Firma Rentschler über die Wirkungsweise von Interferon-y bei der PcP entdeckte ich, daß Rheumatiker, die außerdem noch an Diabetes mellitus Typ II erkrankt waren, sowohl von ihrem Rheumaleiden als auch gleichzeitig vom Diabetes mellitus Typ II geheilt wurden.While participating in a therapy study for the Rentschler company I discovered about the mode of action of interferon-y in PcP that Rheumatics who also suffer from type II diabetes mellitus were both from their rheumatic ailment and at the same time from Type II diabetes mellitus have been cured.

Bei Patienten mit Diabetes vom Typ I hatte ich teilweise Erfolg. Der Heilungsprozeß dauert 1 Jahr.I have had some success with type I diabetes. The The healing process takes 1 year.

Diabetiker vom Typ I wurden durch Interferon-y nur teilweise geheilt und zwar dann, wenn eine Restfunktion der ′β- Langerhans′schen Inselzellen noch vorhanden war.Type I diabetes was only partially cured by interferon-y and if a residual function of the 'β-Langerhans islet cells was still there.

Bei einer Studie in Middlesex, London wurde beobachtet, daß Diabetiker gegenüber Gesunden vermehrt Antigene an den Zellwänden der β-Langer­ hans′schen Inselzellen besitzen. Diese Antigene bilden sich unter dem Ein­ fluß von Interteron-y an den Zellwänden zurück und es kommt zu einer Suppression der Autoimmun-Antikörperbildung. Die β-Langerhans′schen lnselzellen können sich dadurch regenerieren und dem Organismus das erforderliche Insulin wieder bereitstellen. A study in Middlesex, London observed that diabetics antigens on the cell walls of the β-Langer increased compared to healthy individuals own Hansian islet cells. These antigens form under the one flow back from Interteron-y to the cell walls and there is a Suppression of autoimmune antibody formation. The β-Langerhans'schen As a result, island cells can regenerate and the organism Provide the necessary insulin again.  

Eine erfolgreiche Therapie mit Interferon-y kann man seit ca. 1 Jahr bei Diabetikern applizieren, nachdem man ebenso mit diesen Medikamenten bei Rheumatikern große Erfolge vorweisen konnte.Successful therapy with interferon-y has been around for about 1 year in diabetics apply after having also used these medications for rheumatics Was able to show success.

In Expertenkreisen ist man der Auffassung, daß es sich dabei um eine Immunmodulation handelt, ohne sich darüber bewußt zu sein, wie das eigentlich funktioniert.Experts believe that this is immunomodulation acts without being aware of how it actually works.

Man muß dabei an altbewährte serologische Reaktionen denken, die bei ähnlichen Erkrankungen ,wie z. B. antiimmunhaemmolytischen Anaemien , vorkommen. Unter anderem setzt sich die Vorstellung durch, daß Autoimmunantikörper die β-lnsel­ zellen schädigen und langfristig zerstören. Die Herstellung von Insulin durch die ß-lnselzellen ist dann nicht mehr gewährleistet, wodurch es letztlich zum Ausbruch der Erkrankung Diabetes mellitus I und II kommt Ergebnisse einer Studie in Middle-Essex, London, ergaben, daß Antigene an den Zell­ wänden der β-lnselzellen bei Diabetikern häufiger vorkommen als bei Gesunden. Diese Antigene können das Immunsystem stimulieren, Antikörper zu bilden, welche dann als Autoimmunantikörper betrachtet werden müssen, wenn sie die eigenen β-lnselzellen angreifen, indem sie die Antigene an den Zellwänden besetzen, was man in der Serologie als Antigen-Antikörper-Reaktion oder hier in diesem speziellen Fall als Antigen-Autoimmun­ antikörper-Reaktion bezeichnet.One has to think of well-tried serological reactions, that of similar ones Diseases such as B. antiimmune haemolytic anemias occur. Among other things, the idea prevails that autoimmune antibodies are the β-island damage cells and destroy them in the long term. The production of insulin by the β-island cells are then no longer guaranteed, which ultimately leads to an outbreak the disease Diabetes mellitus I and II comes Results of a study in Middle-Essex, London, revealed that antigens on the cells walls of the β-island cells occur more frequently in diabetics than in healthy people. These Antigens can stimulate the immune system to produce antibodies, which are then called Autoimmune antibodies must be considered when they own β-island cells attack by occupying the antigens on the cell walls, which is what in serology as an antigen-antibody reaction or here in this special case as an antigen autoimmune called antibody reaction.

Nach meiner Auffassung kommt es beim Diabetes mellitus durch diese Reaktion langfristig zum Zelltod der β-lnselzellen. Interferon-y blockiert diese Autoimmunreaktion und verhindert damit die Degeneration der β-lnselzellen und zwar durch Supression der Autoimmun­ antikörper vermutlich durch Abbau der Antigene an den Zellwänden der β-lnselzellen, wobei als Folge eine Stimulation des Immunsystems, Antikörper zu bilden, ausbleibt. Interferon-y zeigt keine Nebenwirkungen, die auf eine Schwächung des Immunsystems zurückzuführen wären. Somit schwächt Interferon-y das Immunsystem nicht, sondern es moduliert es in einer Weise, daß die Autoaggressivität bei Diabetes und Rheuma ausbleibt.In my opinion, this reaction causes diabetes mellitus in the long term on cell death of β-island cells. Interferon-y blocks and prevents this autoimmune reaction with it the degeneration of the β-island cells by suppression of the autoimmune antibodies presumably by breaking down the antigens on the cell walls of the β-island cells, as a result, there is no stimulation of the immune system to produce antibodies. Interferon-y shows no side effects due to a weakened immune system would be due. So interferon-y does not weaken the immune system, rather it modulates it in such a way that the auto-aggressiveness in diabetes and rheumatism is absent.

Claims (1)

Heilung der Krankheiten "P.c.P" und "Diabetes mellitu" gekennzeichnet durch die Behandlung mit Interferon- Gamma.Healing of the diseases "PcP" and "Diabetes mellitu" characterized by the treatment with interferon gamma.
DE19924238159 1992-11-12 1992-11-12 Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon Ceased DE4238159A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19924238159 DE4238159A1 (en) 1992-11-12 1992-11-12 Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924238159 DE4238159A1 (en) 1992-11-12 1992-11-12 Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon

Publications (1)

Publication Number Publication Date
DE4238159A1 true DE4238159A1 (en) 1993-04-29

Family

ID=6472685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19924238159 Ceased DE4238159A1 (en) 1992-11-12 1992-11-12 Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon

Country Status (1)

Country Link
DE (1) DE4238159A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0744949A1 (en) * 1994-02-18 1996-12-04 Georgetown University Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3436638A1 (en) * 1984-10-05 1986-04-17 Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim USE OF INTERFERON GAMMA (IFN-GAMMA) PREPARATIONS CONTAINING RHEUMATIC DISEASES
DE3519361A1 (en) * 1985-05-30 1986-12-04 Boehringer Ingelheim International GmbH, 6507 Ingelheim (GAMMA) -IFN AS AN ACTIVE SUBSTANCE FOR INHIBITING (PREVENTING) DEGREASING PROCESSES IN THE BONE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3436638A1 (en) * 1984-10-05 1986-04-17 Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim USE OF INTERFERON GAMMA (IFN-GAMMA) PREPARATIONS CONTAINING RHEUMATIC DISEASES
DE3519361A1 (en) * 1985-05-30 1986-12-04 Boehringer Ingelheim International GmbH, 6507 Ingelheim (GAMMA) -IFN AS AN ACTIVE SUBSTANCE FOR INHIBITING (PREVENTING) DEGREASING PROCESSES IN THE BONE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemcial Patents Index, Ref. Nr. 91-033720/05 zu JP 2304-029-A, Documentation Abstracts Journal, Section D: Food, Detergants, Derwent Publications Ltd., London *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0744949A1 (en) * 1994-02-18 1996-12-04 Georgetown University Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration
EP0744949A4 (en) * 1994-02-18 2000-03-01 Univ Georgetown Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration

Similar Documents

Publication Publication Date Title
DE69126304T2 (en) METHOD AND COMPOSITION FOR TREATING DISEASES OF THE CNS CAUSED BY ABNORMAL BETA AMYLOID PROTEIN
Freeman et al. Fluoxetine as a treatment for bulimia nervosa
Savage The resolution and subsequent remobilization of resistance by LSD in psychotherapy
Vassella et al. Asymmetric tonic neck reflex: a review of the literature and a study of its presence in the neonatal period
DE3875859T2 (en) PREPARATIONS FOR IMPROVING ADCC THERAPIES.
Barontini et al. The nosological position of Fisher's syndrome (ophthalmoplegia, ataxia and areflexia)
DE4238159A1 (en) Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon
MAY et al. Parkinsonian reactions following chlorpromazine and reserpine: Similar reactions in the same patients
Wakusawa et al. Triadic Therapy Based on Somatic Eye Movement Desensitization and Reprocessing for Complex Posttraumatic Stress Disorder: A Pilot Randomized Controlled Study.
Rosenthal Alterations in serum thyroxine with cerebral electrotherapy (electrosleep)
Forgays Flotation REST as a smoking intervention
Izzedine et al. Vergleichende Serumuntersuchungen über Verhalten und Bedeutung von Autoantikörpern und Fermentaktivität bei Leberkrankheiten
Olatawura Psychotherapy for the Nigerian patient. Some aspects of the problems involved
Frankel Treatment of a multisymptomatic phobic by a self-directed, self-reinforced imagery technique: A case study.
Eccles et al. In vivo desensitization in the treatment of recurrent nightmares
Thomas et al. Preliminary studies with azapropazone in gout and hyperuricaemia
Guskova Radiation and human brain
Kuruvilla USEFULNESS QF BEHAVIOUR THERAPY TECHNIQUES IN THE TREATMENT OF PSYCHOGENIC IMPOTENCE
Hulse Communalization as an active psychotherapeutic group process
Dibner et al. Screening for psychotherapy by an open-ended group
DE2413641A1 (en) PROCESS FOR MANUFACTURING MEDICINES FOR TREATMENT OF NEOPLASIS, INFECTIONS, FOR NON-SPECIFIC IMMUNITY STIMULATION, AND PRODUCTS OF SUPPORT FOR ACTIVE IMMUNOTHERAPY AND VACCINATIONS, AND MEDICATION FROM THEM
DE3513391A1 (en) Nootropic composition
Rubin et al. Effectiveness of a three month methadone program
Polk Treatment of exhibitionism in a 38-year-old male by hypnotically assisted covert sensitization
Ohayon Manifestations of a punitive superego

Legal Events

Date Code Title Description
OAV Applicant agreed to the publication of the unexamined application as to paragraph 31 lit. 2 z1
OP8 Request for examination as to paragraph 44 patent law
OR8 Request for search as to paragraph 43 lit. 1 sentence 1 patent law
8105 Search report available
8122 Nonbinding interest in granting licenses declared
8131 Rejection